Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[131 iodine and differentiated thyroid cancers]

M J Delisle1, C Schvartz

  • 1Institut Jean Godinot, Reims.

Annales D'Endocrinologie
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are dietary reports in a case-control study on thyroid cancer biased by risk perception of Chernobyl fallout?

Revue d'epidemiologie et de sante publique·2017
Same author

Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France.

Cancer epidemiology·2015
Same author

Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.

The Journal of clinical endocrinology and metabolism·2011
Same author

Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines.

The Journal of clinical endocrinology and metabolism·2010
Same author

[Time trends in the geographic variation of thyroid cancer incidence by tumor size from 1983 to 2000 in France].

Revue d'epidemiologie et de sante publique·2009
Same author

Cancer incidence and mortality in France over the period 1980-2005.

Revue d'epidemiologie et de sante publique·2008
Same journal

[18F]F-DOPA and [18F]F-FDG PET/CT for staging advanced medullary thyroid cancer.

Annales d'endocrinologie·2026
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
See all related articles

Radioactive iodine (131I) effectively treats differentiated thyroid cancer by targeting residual or metastatic tumors. Careful patient selection and dosimetry are crucial for optimal outcomes and safety in thyroid cancer management.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Endocrinology

Background:

  • Differentiated thyroid carcinoma (DTC) management involves addressing residual disease and metastases.
  • Radioactive iodine-131 (131I) offers both diagnostic and therapeutic capabilities due to its dual gamma and beta emissions.

Purpose of the Study:

  • To evaluate the indications and efficacy of 131I in treating differentiated thyroid carcinoma.
  • To highlight the importance of prognostic factors and surgical quality in guiding 131I therapy.
  • To emphasize the role of 131I in detecting and treating recurrences and metastases, especially in cases with elevated thyroglobulin levels and negative scintigraphy.

Main Methods:

  • Retrospective analysis of patient data to assess 131I efficacy.
  • Utilizing 131I for post-surgical remnant ablation, detection, and treatment of recurrences and metastases.

Related Experiment Videos

  • Employing therapeutic doses of 131I for early diagnosis and cure of metastases in patients with isolated thyroglobulin elevation.
  • Implementing specific dosimetric and radioprotection measures.
  • Conducting scintigraphic detection under optimal technical conditions.
  • Long-term follow-up using thyroglobulin dosages and 131I whole-body scintigraphy.

    • Main Results:

    • 131I is recommended for post-surgical remnant ablation, recurrence detection/treatment, and distant metastases management.
    • Therapeutic 131I doses aid in early diagnosis and cure of metastases with negative diagnostic scintigraphy when thyroglobulin is elevated.
    • Early diagnosis and positive response to 131I irradiation correlate with favorable remission rates.
    • Repeated treatments by specialized teams improve survival quality for metastatic patients, even without complete remission.

    Conclusions:

    • 131I is a valuable tool for differentiated thyroid carcinoma, but its use should be guided by prognostic factors and surgical quality.
    • Strategic application of 131I, particularly in cases of elevated thyroglobulin, enhances early diagnosis and treatment of metastases.
    • Adherence to dosimetric and radioprotection guidelines is essential for safe and effective 131I therapy.
    • Protracted follow-up and repeated treatments contribute to improved outcomes and quality of life for patients with metastatic disease.